Skip to main content

Table 1 Checklist of health outcomes and costs included under payer’s perspective as per the Impact Inventory Template given by Second Panel on Cost-Effectiveness in Health and Medicine

From: Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States

Type of Impact (list category within each sector with unit of measure if relevant)

Included in This Base Case Analysis From payer’s perspective (Yes/No)

Health outcomes (effects)

 Longevity effects

Yes

 Health-related quality-of-life effects

Yes

 Other health effects (eg, adverse events and secondary transmissions of infections)

No

Medical costs

 Paid for by third-party payers

Yes

 Paid for by patients out-of-pocket

No

 Future related medical costs (payers)

Yes

 Future related medical costs (patients)

No

 Future unrelated medical costs (payers)

No

 Future unrelated medical costs (patients)

No